Head-To-Head Review: Anteris Technologies Global (NASDAQ:AVR) and NanoVibronix (NASDAQ:NAOV)

NanoVibronix (NASDAQ:NAOV) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for NanoVibronix and Anteris Technologies Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoVibronix	0	0	0	0	0.00
Anteris Technologies Global	0	0	4	0	3.00

Anteris Technologies Global has a consensus price target of $16.50, indicating a potential upside of 334.21%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than NanoVibronix.

Institutional & Insider Ownership

16.4% of NanoVibronix shares are owned by institutional investors. 7.0% of NanoVibronix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares NanoVibronix and Anteris Technologies Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NanoVibronix	-93.80%	-101.17%	-53.03%
Anteris Technologies Global	N/A	N/A	N/A

Valuation and Earnings

This table compares NanoVibronix and Anteris Technologies Global”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoVibronix	$3.29 million	0.91	-$3.71 million	($13.53)	-0.28
Anteris Technologies Global	$2.71 million	50.49	N/A	N/A	N/A

Anteris Technologies Global has lower revenue, but higher earnings than NanoVibronix.

Summary

Anteris Technologies Global beats NanoVibronix on 7 of the 10 factors compared between the two stocks.

About NanoVibronix

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.